A randomised cross over pilot study of inhaled tobramycin as a treatment option for hospitalised patients with cystic fibrosis versus standard treatment of intravenous tobramyci
Phase 4
Recruiting
- Conditions
- Cystic FibrosisInfection - Studies of infection and infectious agents
- Registration Number
- ACTRN12609000016235
- Lead Sponsor
- Royal Adelaide Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Diagnosis of cystic fibrosis, chronically colonised with Pseudomonas aeruginosa, Forced Expiratory Volume in 1 second (FEV1) > 25%, having an exacerbation of their lung infection
Exclusion Criteria
Patients who are pyrexial with a temperature of >38.0C , allergic to aminoglycosides, patients with calculated creatinine clearance <50mL/min/1.73m2
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method